Compare ADX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADX | BEAM |
|---|---|---|
| Founded | 1840 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | ADX | BEAM |
|---|---|---|
| Price | $23.25 | $30.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $46.00 |
| AVG Volume (30 Days) | 182.4K | ★ 2.0M |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | ★ 6.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,701,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.94 | $13.53 |
| 52 Week High | $19.57 | $36.44 |
| Indicator | ADX | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 51.42 | 52.77 |
| Support Level | $23.17 | $30.16 |
| Resistance Level | $23.69 | $35.34 |
| Average True Range (ATR) | 0.24 | 2.67 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 53.76 | 37.84 |
Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally managed closed-end fund whose investment objectives are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It invests a majority of its assets in very liquid S&P 500 stocks, and has broad flexibility in the selection of stocks, but maintains a sector neutral approach. The fund has a diversified equity portfolio which consists of securities of companies from energy, consumer staples, information technology, financials, and other sectors.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.